Literature DB >> 15308167

Biodistribution of p-borophenylalanine (BPA) in dogs with spontaneous undifferentiated thyroid carcinoma (UTC).

M A Dagrosa1, M Viaggi, R Jimenez Rebagliati, V A Castillo, D Batistoni, R L Cabrini, S Castiglia, G J Juvenal, M A Pisarev.   

Abstract

Human undifferentiated thyroid carcinoma (UTC) is a very aggressive tumor which lacks an adequate treatment. The UTC human cell line ARO has a selective uptake of BPA in vitro and after transplanting into nude mice. Applications of boron neutron capture therapy (BNCT) to mice showed a 100% control of growth and a 50% histological cure of tumors with an initial volume of 50 mm(3) or less. As a further step towards the potential application in humans we have performed the present studies. Four dogs with diagnosis of spontaneous UTC were studied. A BPA-fructose solution was infused during 60 min and dogs were submitted to thyroidectomy. Samples of blood and from different areas of the tumors (and in one dog from normal thyroid) were obtained and the boron was determined by ICP-OES. Selective BPA uptake by the tumor was found in all animals, the tumor/blood ratios ranged between 2.02 and 3.76, while the tumor/normal thyroid ratio was 6.78. Individual samples had tumor/blood ratios between 8.36 and 0.33. These ratios were related to the two histological patterns observed: homogeneous and heterogeneous tumors. We confirm the selective uptake of BPA by spontaneous UTC in dogs and plan to apply BNCT in the future.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15308167     DOI: 10.1016/j.apradiso.2004.05.006

Source DB:  PubMed          Journal:  Appl Radiat Isot        ISSN: 0969-8043            Impact factor:   1.513


  2 in total

1.  Histopathological changes of testes and eyes by neutron irradiation with boron compounds in mice.

Authors:  Yeon-Joo Kim; Won-Ki Yoon; Si-Yun Ryu; Ki-Jung Chun; Hwa-Young Son; Sung-Whan Cho
Journal:  J Vet Sci       Date:  2006-03       Impact factor: 1.672

2.  Closo-Carboranyl- and Metallacarboranyl [1,2,3]triazolyl-Decorated Lapatinib-Scaffold for Cancer Therapy Combining Tyrosine Kinase Inhibition and Boron Neutron Capture Therapy.

Authors:  Marcos Couto; Catalina Alamón; María Fernanda García; Mariángeles Kovacs; Emiliano Trias; Susana Nievas; Emiliano Pozzi; Paula Curotto; Silvia Thorp; María Alejandra Dagrosa; Francesc Teixidor; Clara Viñas; Hugo Cerecetto
Journal:  Cells       Date:  2020-06-05       Impact factor: 6.600

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.